{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T06:40:21Z","timestamp":1767163221518,"version":"build-2238731810"},"reference-count":31,"publisher":"Wiley","issue":"9","license":[{"start":{"date-parts":[[2013,9,4]],"date-time":"2013-09-04T00:00:00Z","timestamp":1378252800000},"content-version":"vor","delay-in-days":3,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2013,9]]},"abstract":"Abstract<\/jats:title>\n \n Background<\/jats:title>\n \n Statins are associated with skeletal muscle adverse effects. These are generally considered mild and reversible, with more severe toxicity occurring rarely. There is little known regarding statin myotoxicity in\n A<\/jats:styled-content>\n boriginal and\n T<\/jats:styled-content>\n orres\n S<\/jats:styled-content>\n trait\n I<\/jats:styled-content>\n slander\n A<\/jats:styled-content>\n ustralians who are at high cardiovascular risk and likely to receive statins.\n <\/jats:p>\n <\/jats:sec>\n \n Aims<\/jats:title>\n \n To describe features of serious statin\u2010associated myotoxicity (\n SSAM<\/jats:styled-content>\n ) occurring in Indigenous\n A<\/jats:styled-content>\n ustralians and increase awareness of this condition.\n <\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n \n Observational case series of\n SSAM<\/jats:styled-content>\n in\n A<\/jats:styled-content>\n boriginal or\n T<\/jats:styled-content>\n orres\n S<\/jats:styled-content>\n trait\n I<\/jats:styled-content>\n slanders. Cases were identified from personal clinical experience, referrals, reports to the\n T<\/jats:styled-content>\n herapeutic\n G<\/jats:styled-content>\n oods\n A<\/jats:styled-content>\n dministration, medical literature, an Internet search and reports from a histopathology laboratory. Information was collected onto a standardised data collection form.\n <\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n \n Fifteen cases of serious myotoxicity in\n A<\/jats:styled-content>\n boriginal or\n T<\/jats:styled-content>\n orres\n S<\/jats:styled-content>\n trait\n I<\/jats:styled-content>\n slanders exposed to statins were identified from 2006 to 2012. The mean age was 55 (range 35\u201369). Painless weakness was the most common presentation. Interacting drugs were involved in seven cases. Biopsies were done in eight cases, three showed inflammatory polymyositis and five necrotising myositis. Three patients died and two had permanent severe disability. Resolution of symptoms after statin cessation was variable.\n <\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n \n SSAM<\/jats:styled-content>\n has occurred in the Indigenous\n A<\/jats:styled-content>\n ustralian population with some fatalities. Awareness of the potential for\n SSAM<\/jats:styled-content>\n is essential for early recognition and effective management to reduce probability of avoidable catastrophic harm. Safe, as well as effective use of medication, is essential for optimum health outcomes. Effective pharmacovigilance and therapeutic risk management are important for\n A<\/jats:styled-content>\n boriginal and\n T<\/jats:styled-content>\n orres\n S<\/jats:styled-content>\n trait\n I<\/jats:styled-content>\n slander\n A<\/jats:styled-content>\n ustralians.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1111\/imj.12196","type":"journal-article","created":{"date-parts":[[2013,5,21]],"date-time":"2013-05-21T03:52:03Z","timestamp":1369108323000},"page":"987-992","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Serious statin\u2010associated myotoxicity and rhabdomyolysis in\n A<\/scp>\n boriginal and\n T<\/scp>\n orres\n S<\/scp>\n trait\n I<\/scp>\n slanders: a case series"],"prefix":"10.1111","volume":"43","author":[{"given":"G. M.","family":"Gabb","sequence":"first","affiliation":[{"name":"Department of General Medicine Royal Adelaide Hospital Adelaide South Australia Australia"},{"name":"Department of Medicine University of Adelaide Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Vitry","sequence":"additional","affiliation":[{"name":"Quality Use of Medicines and Pharmacy Research Centre, Sansom Institute for Health Research, School of Pharmacy and Medical Sciences University of South Australia Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Limaye","sequence":"additional","affiliation":[{"name":"Department of Rheumatology Royal Adelaide Hospital Adelaide South Australia Australia"},{"name":"Department of Medicine University of Adelaide Adelaide South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Alhami","sequence":"additional","affiliation":[{"name":"Department of Medicine Goulburn Valley Health Care Goulburn Valley South Australia Australia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,4]]},"reference":[{"key":"e_1_2_6_2_1","unstructured":"Pharmaceutical Benefits Advisory Committee.Review of statin therapies[cited 2013 May 7]. Available from URL:http:\/\/www.pbs.gov.au\/info\/industry\/listing\/elements\/pbac\u2010meetings\/psd\/2012\u201007\/review\u2010of\u2010statin\u2010therapies"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11926-010-0104-3"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1711"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.20567"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1002\/mus.21486"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2006.10.007"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/hrt.2010.199034"},{"key":"e_1_2_6_9_1","volume-title":"Cardiovascular Disease and Its Associated Risk Factors in Aboriginal and Torres Strait Islander Peoples 2004\u201305","author":"Penm E","year":"2008"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.hlc.2005.10.010"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.18773\/austprescr.2011.025"},{"key":"e_1_2_6_12_1","unstructured":"Food and Drug Administration.Guidance for industry: good pharmacovigilance practices and pharmacoepidemiologic assessment[cited 2013 Mar 14]. Available from URL:http:\/\/www.fda.gov\/downloads\/regulatoryinformation\/guidances\/ucm126834.pdf"},{"key":"e_1_2_6_13_1","volume-title":"Fatal Statin Related Myositis in Australian Indigenous Patients","author":"Alhami G","year":"2010"},{"key":"e_1_2_6_14_1","first-page":"P2","article-title":"Fatal statin\u2010induced rhabdomyolysis in the Australian indigenous population and vitamin D replacement \u2013 new concepts","volume":"32","author":"Gerrard G","year":"2011","journal-title":"Endocr Rev"},{"key":"e_1_2_6_15_1","unstructured":"Australian Government Department of Health and Ageing Therapeutic Goods Administration.Australian requirements and recommendations for pharmacovigilance responsibilities of sponsors of medicines[cited 2013 Mar 14]. Available from URL:http:\/\/www.tga.gov.au\/safety\/australian\u2010pharmacovigilance\u2010sponsors.htm"},{"key":"e_1_2_6_16_1","unstructured":"Food and Drug Administration.Collection of race and ethnicity data in clinical trials. Guidance for industry \u2013 collection of race and ethnicity data in clinical trials[cited 2013 Mar 5] Available from URL:http:\/\/www.fda.gov\/RegulatoryInformation\/Guidances\/ucm126340.htm"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejim.2012.01.004"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.trsl.2008.11.002"},{"key":"e_1_2_6_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.atherosclerosis.2011.11.005"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2990.2010.01153.x"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.1993.tb137693.x"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(89)91793-5"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0801936"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2350-12-136"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1535"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.5694\/j.1326-5377.2009.tb02811.x"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.292.21.2585"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2125.2008.03308.x"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.22.17.1524.34130"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjcard.2005.12.010"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1097\/00124743-200110000-00019"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.075523"}],"updated-by":[{"DOI":"10.1111\/imj.13054","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2016,5,11]],"date-time":"2016-05-11T00:00:00Z","timestamp":1462924800000}}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12196","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12196","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T23:28:55Z","timestamp":1696202935000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9]]},"references-count":31,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,9]]}},"alternative-id":["10.1111\/imj.12196"],"URL":"https:\/\/doi.org\/10.1111\/imj.12196","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9]]},"assertion":[{"value":"2013-04-08","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-05-08","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-09-04","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}